AusCann Welcomes The Passing of Medicinal Cannabis Legislation Amendment

By:
DayaCann AusCann Group Holdings - Medical Liaison Managers placement Tasmanian Alkaloids and Chilean License

CARABOODA, Western Australia, Oct. 20, 2017 /Weed Wire/ — AusCann Group Holdings Ltd (ASX:AC8 or ‘the Company’) welcomes the passing of the Medicinal Cannabis Legislation Amendment (Securing Patient Access) Bill 2017 (the Bill) in the Senate yesterday.

The Bill was introduced to expand upon the ability of terminally ill patients to access cannabinoid medicines through the Therapeutic Goods Administration (TGA) Special Access Scheme Category A.
Unlike other TGA access schemes which enable doctors to prescribe cannabinoid medicines, under the TGA Special Access Scheme Category A doctors may prescribe to terminally ill patients without waiting for prior approval from the TGA.

Currently, these Category A, terminally ill patients can only access cannabinoid medicines that are imported on a patient by patient basis.

This Bill will enable these terminally ill patients to access cannabinoid medicines that are produced by AusCann in Australia as well as those medicines being imported by AusCann.

Through its strategic partnership with Canopy Growth Corporation, AusCann is able to import cannabinoid medicines that are already being used to treat patients in Canada.

The Bill has now progressed and has been introduced to the House of Representatives for debate. AusCann is closely monitoring the progress of this Bill and looks forward to the pending legislative change being implemented.

In the interim, AusCann’s Medical Liaison Managers are actively working with Australian doctors that are able to prescribe AusCann’s cannabinoid medicines under the TGA’s other access schemes to enable access to these medicines for those patients in need.

Elaine Darby, Managing Director, AusCann commented: “We welcome the introduction of any measures that further enhances the ability of terminally ill patients to access medications their doctors believe can assist them. We look forward to being able to supply these Australian patients with high quality, cost effective, clinically validated medications that have been produced in Australia.”

For more information please contact
AusCann
Elaine Darby
Managing Director
elaine.darby@auscann.com.au
+61 8 9561 8834

For Investment Enquires
Stewart Washer
Stewart.washer@auscann.com.au
+61 418 288 212

For Media Enquiries
Caroline Zielinski
Media & Capital Partners
Caroline.zielinski@mcpartners.com.au
+61 400 172 145

ABOUT AUSCANN GROUP
AusCann is an Australian based company that was incorporated in September 2014 with the aim of producing and providing high quality, economical and clinically validated cannabis medicines to patients. It is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products and has built a strong team of experts and partners with international connections. Partners includes TSX listed Canopy Growth Corporations the largest producer of medicinal cannabis in North America, DayaCann, the only licensed medicinal cannabis grower in Chile and Tasmanian Alkaloids, producer of ~40% of the world’s opiates.

Weed Wire disseminates press releases from companies and organizations in the legal marijuana industry. Email weedwire@mjic.com to have your press release added.

Related posts

Top